Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

John Whelan

Bill Picht

Brian Farrer

Jeff Hutchins

Thomas Moench

Sam Lai

The board of directors at Inhalon has a long history of experience with various companies in different industries. They have all been educated at Yale University and Skidmore College in Chemistry and Biochemistry, respectively. They have held positions such as Board Director and Executive Advisor at Saccharo Inc., Kryptos Biotechnolgies, Inc., and Chameleon Biosciences, Inc. In addition, they have also been a Board Director at Life Science Angels.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Inhalon

Leadership Team

CEO and Executive Team